Our aim is to create a product allowing for higher precision and less side effects of prostate cancer focal radiotherapy. NanoThea is able to achieve this by closing well known radioisotopes in our polysaccharide nanoparticles and targeting system. The unique features of our product are:
- the nanoparticles’ structure allows high tumor/blood ratio, increasing safety of the radiotherapy
- appropriate engineered linker for targeting molecule
- radiochemical stability
- lack of toxicity of the carrier – materials approved by FDA for safety (dextran)
- radiolabeling in situ in the hospital, before administration

NANOTARGET
It is an innovative radiopharmaceutical for prostate cancer treatment for patients with metastatic tumors that are resistant to currently applied therapies. The developed nanoparticles will be precise carriers of radioactive isotopes, which are safe for users. The nanoparticle will be conjugated with the isotope at the place of delivery (e.g. a hospital), to increa...
Our aim is to create a product allowing for higher precision and less side effects of prostate cancer focal radiotherapy. NanoThea is able to achieve this by closing well known radioisotopes in our polysaccharide nanoparticles and targeting system. The unique features of our product are:
- the nanoparticles’ structure allows high tumor/blood ratio, increasing safety of the radiotherapy
- appropriate engineered linker for targeting molecule
- radiochemical stability
- lack of toxicity of the carrier – materials approved by FDA for safety (dextran)
- radiolabeling in situ in the hospital, before administration

NANOTARGET
It is an innovative radiopharmaceutical for prostate cancer treatment for patients with metastatic tumors that are resistant to currently applied therapies. The developed nanoparticles will be precise carriers of radioactive isotopes, which are safe for users. The nanoparticle will be conjugated with the isotope at the place of delivery (e.g. a hospital), to increase the availability of the test and reduce its cost.
This advanced approach to the radioisotope carrier focuses on maximizing availability of nanoparticles for cancer cells spread within the organism. To maximize the efficiency, our product is characterized with higher tumor/blood ratio compared to current solutions.
The structure of nanoparticles is composed solely from biodegradable materials digested by humans. Chemistry is carried out with no use of toxic solvents. In addition, the nanoparticle has a “cloud” structure composed of 90% water. Highly specific molecules for prostate cancer targeting provide high specificity of action.
More information

Employees

Grzegorz Pikus
Admin
Grzegorz Pikus Organic Chemist Organic Chemist at NanoThea
Kamil Kopeć
Admin
Magdalena Janczewska
Admin
Magdalena Janczewska CEO Biotechnologist with several ideas to translate from scientific idea to real product.
Jolanta Duszak
Admin
Jolanta Duszak
Michał Szkop
Admin
Michał Szkop
Michał Żuk
Admin
Michał Żuk
Anna Świątkowska
Admin
Anna Świątkowska